Post by icemandios on Jan 31, 2022 20:47:15 GMT
January 31, 2022 02:21 PM EST R&D
The big shakeup at a badly rattled Biogen continues as 2 longtime board members hit the exits
John Carroll
Editor & Founder
In recent weeks we’ve seen Biogen’s CSO exit under pressure and senior marketing execs leave in an exodus as the company recoiled from a fierce backlash against the FDA’s ultra controversial approval of Aduhelm for Alzheimer’s.
Now 2 longtime board members are on the way out as well as aftershocks continue to rattle the big biotech, with all the customary handshakes and congratulatory notes you might expect.
The two are Nancy Leaming and Brian Posner, who will make their departure formal at the annual meeting. Leaming served on the audit committee while Posner chaired the compensation committee.
No reasons were given for their decisions to leave the posts — which come with hundreds of thousands in annual income. Leaming picked up $422,333 in comp in 2020, while Posner gathered $444,643. But the departures arrive as Biogen is engaged in an existential struggle to persuade Medicare to change an initial decision to severely limit reimbursement for Aduhelm to a tiny group of patients in clinical trials.
So far, the drug has only managed to gain marginal traction in the market as criticism continues to roast the FDA for its decision to provide an accelerated approval with little hard evidence it works.
For his part, Posner congratulated the company’s R&D work, citing the success of their Alzheimer’s drug, while Leaming limited herself to heralding Biogen as it “remains steadfast in its commitment to deliver responsibly and transparently both for shareholders and for patients, and I look forward to following its future progress as it continues on its mission to pioneer and lead in neuroscience in a manner that is beneficial to its many stakeholders.”
The big shakeup at a badly rattled Biogen continues as 2 longtime board members hit the exits
John Carroll
Editor & Founder
In recent weeks we’ve seen Biogen’s CSO exit under pressure and senior marketing execs leave in an exodus as the company recoiled from a fierce backlash against the FDA’s ultra controversial approval of Aduhelm for Alzheimer’s.
Now 2 longtime board members are on the way out as well as aftershocks continue to rattle the big biotech, with all the customary handshakes and congratulatory notes you might expect.
The two are Nancy Leaming and Brian Posner, who will make their departure formal at the annual meeting. Leaming served on the audit committee while Posner chaired the compensation committee.
No reasons were given for their decisions to leave the posts — which come with hundreds of thousands in annual income. Leaming picked up $422,333 in comp in 2020, while Posner gathered $444,643. But the departures arrive as Biogen is engaged in an existential struggle to persuade Medicare to change an initial decision to severely limit reimbursement for Aduhelm to a tiny group of patients in clinical trials.
So far, the drug has only managed to gain marginal traction in the market as criticism continues to roast the FDA for its decision to provide an accelerated approval with little hard evidence it works.
For his part, Posner congratulated the company’s R&D work, citing the success of their Alzheimer’s drug, while Leaming limited herself to heralding Biogen as it “remains steadfast in its commitment to deliver responsibly and transparently both for shareholders and for patients, and I look forward to following its future progress as it continues on its mission to pioneer and lead in neuroscience in a manner that is beneficial to its many stakeholders.”